Mindmed collaborators prof. liechti and dr. holze announce positive topline data from phase 2 trial evaluating lsd in anxiety disorders

- results from the placebo-controlled investigator-initiated trial, conducted at the university hospital basel (uhb), demonstrate the significant, long-lasting beneficial effects of lsd and potential to safely mitigate symptoms of anxiety and depression - - data further validates mindmed's therapeutic approach and supports the clinical development of mm-120 for the treatment of generalized anxiety disorder - - data was featured in an oral presentation on may 11, 2022 at 5:05am edt / 10:05am bst - new york , may 11, 2022 /prnewswire/ -- mind medicine (mindmed) inc (nasdaq: mnmd), (neo: mmed), (the "company" or "mindmed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that prof. matthias liechti and dr. friederike holze, mindmed collaborators at university hospital basel (uhb), have released positive topline data from a phase 2 placebo-controlled investigator-initiated clinical trial evaluating lsd in the treatment of anxiety disorders.
MNMD Ratings Summary
MNMD Quant Ranking